Impact of COVID-19 on Spinraza Managed Access Agreement
Read NICE statement about the impact of COVID-19 on access to Spinraza.
Read more-
Impact of COVID-19 on Translarna Managed Access Agreement
03/04/2020Read NICE statement about the impact of COVID-19 on access to Translarna.
-
SMA gene therapy Zolgensma given positive opinion
27/03/2020The SMA gene therapy Zolgensma has today been given a positive opinion by the European Medicines Agency (EMA).
-
Impact of new coronavirus laws
26/03/2020On 25 March new measures to deal with the coronavirus outbreak became law in the Coronavirus Act 2020.
-
COVID-19: an open letter to NICE
24/03/2020An open letter to NICE responding to its guidance on critical care for patients with COVID-19.
-
SMC decision for mexiletine
10/03/2020The Scottish Medicines Consortium has made the decision not to recommend mexiletine.
-
Budget 2020: £30m boost for Changing Places toilets
10/03/2020The campaign for more Changing Places toilets is set to get a major boost, with the Chancellor of the Exchequer, Rishi Sunak, set to announce a £30 million investment in tomorrow’
-
Detailed guidance on risks from coronavirus for people with muscle-wasting conditions
06/03/2020Guidance on risks from coronavirus for people living with muscle-wasting conditions
-
Update: Global Managed Access Programme for Zolgensma
06/03/2020Find out the latest information about the SMA gene therapy access programme.
-
British Science Week 2020
03/03/2020For this year’s British Science Week, the theme of which is “Our Diverse Planet”, we’d like to tell you about some exciting research we’ve funded.
-
Below standard: our report on the benefits system
27/02/2020People living with muscle-wasting conditions are struggling to get the disability benefits they are entitled to, with many enduring financial hardship and unnecessary appeals.